



PSUR - Index

(Sample Document will provide on request)



PART III: TABLE OF CONTENTS

	Page
PART I: TITLE PAGE INCLUDING SIGNATURE	1
<u>PART II: EXECUTIVE SUMMARY</u>	3
<u>PART III: TABLE OF CONTENTS</u>	6
<u>1. INTRODUCTION</u>	9
<u>2. WORLDWIDE MARKET AUTHORISATION STATUS</u>	13
<u>3. ACTIONS TAKEN IN THE REPORTING INTERVAL FOR SAFETY REASONS</u>	16
<u>4. CHANGES TO REFERENCE SAFETY INFORMATION</u>	17
<u>5. ESTIMATED EXPOSURE AND USE PATTERNS</u>	18
5.1. <u>CUMULATIVE SUBJECT EXPOSURE IN CLINICAL TRIALS</u>	18
5.2. <u>CUMULATIVE AND INTERVAL PATIENT EXPOSURE FROM MARKETING EXPERIENCE</u>	18
<u>6. DATA IN SUMMARY TABULATIONS</u>	27
6.1. <u>REFERENCE INFORMATION</u>	27
6.2. <u>CUMULATIVE SUMMARY TABULATIONS OF SERIOUS ADVERSE EVENTS IN CLINICAL TRIALS</u>	27
6.3. <u>CUMULATIVE AND INTERVAL SUMMARY TABULATIONS FROM POST-MARKETING DATA SOURCES</u>	27
<u>7. SUMMARIES OF SIGNIFICANT FINDINGS FROM CLINICAL TRIALS DURING THE REPORTING INTERVAL</u>	28
7.1. <u>COMPLETED CLINICAL TRIALS</u>	28
7.2. <u>ON-GOING CLINICAL TRIALS</u>	28
7.3. <u>LONG-TERM FOLLOW-UP</u>	28
7.4. <u>OTHER THERAPEUTIC USE OF THE MEDICINAL PRODUCT</u>	28
7.5. <u>NEW SAFETY DATA RELATED TO FIXED COMBINATION THERAPIES</u>	28
<u>8. FINDINGS FROM NON-INTERVENTIONAL STUDIES</u>	32
<u>9. INFORMATION FROM OTHER CLINICAL TRIALS AND SOURCES</u>	40
<u>10. NON-CLINICAL DATA</u>	40
<u>11. LITERATURE</u>	41
<u>12. OTHER PERIODIC REPORTS</u>	49
<u>13. LACK OF EFFICACY IN CONTROLLED CLINICAL TRIALS</u>	49
<u>14. LATE-BREAKING INFORMATION</u>	50
<u>15. OVERVIEW OF SIGNALS: NEW, ON-GOING OR CLOSED</u>	51
<u>16. SIGNAL AND RISK EVALUATION</u>	52
16.1. <u>SUMMARIES OF SAFETY CONCERNS</u>	52
16.2. <u>SIGNAL EVALUATION</u>	52
16.3. <u>EVALUATION OF RISKS AND NEW INFORMATION</u>	52
16.4. <u>CHARACTERISATION OF RISKS</u>	53
16.5. <u>EFFECTIVENESS OF RISK MINIMISATION (IF APPLICABLE)</u>	53
<u>17. BENEFIT EVALUATION</u>	54



<u>17.1.</u>	<u>IMPORTANT BASELINE EFFICACY AND EFFECTIVENESS INFORMATION</u>	54
<u>17.2.</u>	<u>NEWLY IDENTIFIED INFORMATION ON EFFICACY AND EFFECTIVENESS</u>	54
<u>17.3.</u>	<u>CHARACTERISATION OF BENEFITS</u>	54
18.	<u>INTEGRATED BENEFIT-RISK ANALYSIS FOR AUTHORISED INDICATIONS</u>	55
<u>18.1.</u>	<u>BENEFIT-RISK CONTEXT – MEDICAL NEED AND IMPORTANT ALTERNATIVES</u>	55
<u>18.2.</u>	<u>BENEFIT-RISK ANALYSIS EVALUATION</u>	55
19.	<u>CONCLUSIONS AND ACTIONS</u>	56
20.	<u>APPENDICES TO THE PSUR</u>	58
<u>20.1.</u>	<u>REFERENCE INFORMATION</u>	58
<u>20.2.</u>	<u>CUMULATIVE SUMMARY TABULATIONS OF SERIOUS ADVERSE EVENTS FROM CLINICAL TRIALS</u>	59
<u>20.3.</u>	<u>CUMULATIVE AND INTERVAL SUMMARY TABULATIONS OF SERIOUS AND NON-SERIOUS ADVERSE REACTIONS FROM POST-MARKETING DATA SOURCES</u>	59
<u>20.4.</u>	<u>TABULAR SUMMARY OF SAFETY SIGNALS</u>	59
<u>20.5.</u>	<u>LISTING OF ALL THE MARKETING AUTHORISATION HOLDER-SPONSORED INTERVENTIONAL TRIALS WITH THE PRIMARY AIM OF IDENTIFYING, CHARACTERISING OR QUANTIFYING A SAFETY HAZARD OR CONFIRMING THE SAFETY PROFILE OF THE MEDICINAL PRODUCT</u>	60
<u>20.6.</u>	<u>LISTING OF ALL MARKETING AUTHORISATION HOLDER-SPONSORED NON-INTERVENTIONAL STUDIES CONDUCTED WITH THE PRIMARY AIM OF IDENTIFYING, CHARACTERISING OR QUANTIFYING A SAFETY HAZARD, CONFIRMING THE SAFETY PROFILE OF THE MEDICINAL PRODUCT OR OF MEASURING THE EFFECTIVENESS OF RISK MANAGEMENT MEASURES</u>	60
<u>20.7.</u>	<u>LIST OF THE SOURCES OF INFORMATION USED TO PREPARE THE PSUR</u>	61
<u>20.8.</u>	<u>REGIONAL APPENDIX</u>	65
<u>20.8.1.</u>	<u><i>Proposed product information</i></u>	65
<u>20.8.2.</u>	<u><i>Reference information comparison</i></u>	65
<u>20.8.3.</u>	<u><i>Proposed additional pharmacovigilance and risk minimisation activities</i></u>	65
<u>20.8.4.</u>	<u><i>Summary of on-going safety concerns</i></u>	65
<u>20.8.5.</u>	<u><i>Reporting of results from post-authorisation safety studies</i></u>	65
<u>20.8.6.</u>	<u><i>Effectiveness of risk minimisation</i></u>	65
21.	<u>ABBREVIATIONS & ACRONYMS</u>	66